Biotech company Cynata Therapeutics has begun enrolling patients in their mesenchymal COVID-19 (MEND) trial. The study will explore the efficacy of mesenchymal stem cells in adults diagnosed with severe cases of the virus. “MSCs represent a very promising therapeutic approach to a range of important diseases,” commented company CEO Ross MacDonald. Yourway can transport, store, and distribute even the most challenging drug products, making us the ideal logistics partner provider for all clinical trial needs.